PP
KALV

PDT Partners’s KalVista Pharmaceuticals KALV Stock Holding History

PDT Partners’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-23,654
Closed -$273K – 767
2025
Q1 		$273K Sell
23,654
-11,547
-33% -$118K 0.02% 628
2024
Q4 		$298K Buy
35,201
+12,747
+57% +$132K 0.03% 582
2024
Q3 		$260K Buy
+22,454
New +$282K 0.02% 624
2024
Q2 		– Sell
-41,951
Closed -$498K – 706
2024
Q1 		$498K Buy
+41,951
New +$559K 0.05% 453
2023
Q4 		– Sell
-37,754
Closed -$364K – 606
2023
Q3 		$364K Buy
37,754
+448
+1% +$4.58K 0.05% 451
2023
Q2 		$336K Sell
37,306
-35
-0.1% -$323 0.05% 441
2023
Q1 		$294K Sell
37,341
-9,703
-21% -$72.4K 0.04% 465
2022
Q4 		$318K Buy
+47,044
New +$252K 0.05% 474
2022
Q3 		– Sell
-14,113
Closed -$139K – 960
2022
Q2 		$139K Buy
+14,113
New +$156K 0.01% 864
2020
Q3 		– Sell
-16,325
Closed -$198K – 790
2020
Q2 		$198K Sell
16,325
-2,975
-15% -$31.6K 0.01% 595
2020
Q1 		$148K Sell
19,300
-4,652
-19% -$62.8K 0.01% 586
2019
Q4 		$427K Buy
+23,952
New +$313K 0.03% 452

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

PDT Partners's KALV Position: Q2 2025 in Review

PDT Partners sold out of KalVista Pharmaceuticals (KALV) in Q2 2025, closing a stake of 23,654 shares — an estimated $273K sold.

PDT Partners first reported a position in KALV in Q4 2019 and held it in 12 quarters. The position peaked at $498K in Q1 2024. 139 funds tracked by Wall St. Rank hold KALV as of Q2 2025.

  • PDT Partners reported no remaining KalVista Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • PDT Partners sold 23,654 KalVista Pharmaceuticals shares in Q2 2025, an estimated $273K.
  • PDT Partners first reported a position in KalVista Pharmaceuticals in Q4 2019 and held it in 12 quarters.
  • PDT Partners's KalVista Pharmaceuticals position peaked at $498K in Q1 2024.
  • 139 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2025.

Based on PDT Partners's 13F filing for Q2 2025, filed 14 Aug 2025.